Current Partners

LG Life Sciences

Since April 2000, BioPartners and LG Life Sciences, Ltd. (“LGLS”) have entered into collaborative agreements to jointly develop, manufacture and commercialize a number of biopharmaceutical products, including interferon alpha, human growth hormone (daily and sustained-release formulations) and erythropoietin.

LGLS is the leading pharmaceutical company in South Korea with a firm foundation in R&D.  LGLS strives to improve the health and quality of life of patients around the world through discovery, development and marketing of biopharmaceutical drugs and new chemical entities.

In September 2002, BioPartners entered into collaboration with Rentschler Biotechnologie for the development of a patented HSA-free formulation of interferon beta. Under the terms of the agreement, BioPartners will receive worldwide marketing exclusivity for the indication of multiple sclerosis as well as rights for first refusal for other indications. Rentschler Biotechnologie is a leading German biopharmaceutical contract developer and manufacturer with over 30 years experience in the manufacture of biopharmaceuticals.